(Reuters Health)—Every year since 2006 in the U.S., the number of clinical trials funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
Also by this Author
Analyzing the ClinicalTrials.gov database, researchers found that after trial registration became a requirement for publication in major scientific journals in 2005, the number of newly registered trials rose from 9,321 in 2006 to 18,400 in 2014.
NIH-funded trials dipped slightly from 1,376 in 2006 to 1,048 in 2014, while industry trials increased from 4,585 to 6,550.
Adjusted for inflation, the NIH budget fell by 14% over this period, which may explain some of the decrease, according to the authors of the research letter online Dec. 15 in JAMA.
The pharmaceutical industry tests its own products, while the NIH funds tests of treatment approaches, including lifestyle interventions or drug comparisons, which industry tends not to fund because they do not lead to an increase in their bottom line, says coauthor Dr. Stephan Ehrhardt of Johns Hopkins Bloomberg School of Public Health in Baltimore.
“If we only get industry funded trials off the ground and given that the industry has a vested interest in the outcome of those trials then we don’t get good data to inform health of the public,” Ehrhardt tells Reuters Health by phone.
“I’m a little bit worried about this imbalance,” he says.
Although industry trials did increase, most of the surge in registration was driven by a third “other” category, which included more than 10,000 trials by 2014. These trials were often conducted by researchers outside the U.S. who registered their trials in the U.S. database anyway because ClinicalTrials.gov acts as a de-facto international registry.
Those numbers don’t affect the discussion about NIH funded trials in the U.S., Ehrhardt says.
“Most people trust federal sponsorship more than industry sponsorship,” says Brian P. Kavanagh, chair of the Department of Anesthesia at the University of Toronto, who was not part of the new research letter. “Industry is paying, and naturally hopes to get a specific result, as they are trying to sell a drug.”
“If you’re the average patient you would like to have the best treatment that gives you the least amount of side effects,” and those decisions are made based on NIH funded trials, which do not have a commercial interest in the outcome, says Andrea M. Denicoff of the National Cancer Institute, who was not part of the new study.